Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer - Summary - MDSpire

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer

  • By

  • Soraia Lobo-Martins

  • Diogo Martins-Branco

  • Francine Padonou

  • Hafid Dahma

  • Sigi van den Wijngaert

  • Mounia Jaouart

  • Chiara Dauccia

  • Chiara Molinelli

  • Elisa Agostinetto

  • Angela Loizidou

  • Donatienne Taylor

  • Anais Boisson

  • Soizic Garaud

  • Chloé Spilleboudt

  • Jose Vicente Cardona

  • Peter Ramge

  • Bogdana Ioana Balas

  • Mohammed Bajji

  • Fanny George

  • Tabatha Delsaute

  • Marianne Paesmans

  • Lieveke Ameye

  • Martine Piccart

  • Evandro de Azambuja

  • Karen Willard-Gallo

  • May 20, 2026

  • 0 min

Share

Objective:

To evaluate humoral and cellular immune responses to mRNA SARS-CoV-2 vaccination in cancer patients, emphasizing the importance of understanding immune durability and vaccine efficacy across treatment settings.

Key Findings:
  • All patients developed detectable anti-Spike antibodies, with variability based on cancer type and treatment, highlighting the need for personalized approaches.
  • Patients with hematologic malignancies and/or receiving chemotherapy had the lowest antibody levels, indicating a potential risk factor for reduced vaccine efficacy.
  • Booster doses significantly increased antibody titers, especially in patients in remission or on non-cytotoxic therapies, suggesting the importance of booster strategies.
  • Prior SARS-CoV-2 infection and the number of vaccine doses correlated with better immune responses, underscoring the role of previous exposure.
  • SARS-CoV-2 infection occurred in 16% of the cohort, with infrequent severe cases, indicating the overall effectiveness of vaccination.
Interpretation:

mRNA SARS-CoV-2 vaccines elicit robust immune responses in cancer patients, suggesting the need for tailored vaccination strategies and booster doses to enhance protection in this vulnerable population.

Limitations:
  • Limited data on long-term immunological memory beyond six months, which may affect the understanding of vaccine durability.
  • The study primarily focused on patients with specific cancer types and treatment regimens, which may limit generalizability.
Conclusion:

The findings support the use of booster strategies and tailored vaccination approaches for immunocompromised populations, enhancing protection against COVID-19 and informing public health policy.

Original Source(s)

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer

  • by Soraia Lobo-Martins, Diogo Martins-Branco, Francine Padonou, Hafid Dahma, Sigi van den Wijngaert, Mounia Jaouart, Chiara Dauccia, Chiara Molinelli, Elisa Agostinetto, Angela Loizidou, Donatienne Taylor, Anais Boisson, Soizic Garaud, Chloé Spilleboudt, Jose Vicente Cardona, Peter Ramge, Bogdana Ioana Balas, Mohammed Bajji, Fanny George, Tabatha Delsaute, Marianne Paesmans, Lieveke Ameye, Martine Piccart, Evandro de Azambuja, Karen Willard-Gallo

  • May 20, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen